[Federal Register Volume 81, Number 194 (Thursday, October 6, 2016)]
[Notices]
[Pages 69541-69542]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-24134]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the U.S. patent application listed below may be obtained by 
communicating with the indicated licensing contact at the Technology 
Transfer and Intellectual Property Office, National Institute of 
Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 
20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement 
will be required to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: The invention listed below is owned by an 
agency of the U.S. Government and is available for licensing in the 
U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve 
expeditious commercialization of results of federally-funded research 
and development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing. Technology description follows.
    Use of Roseomonas species to treat eczematous (atopic dermatitis) 
skin disease Description of Technology:
    Atopic dermatitis, also known as eczema, is a chronic itchy skin 
disease that affects over 20% of infants and young children in 
industrialized nations and may persist into adulthood for up to 50% of 
these cases, making it one of the most common skin diseases in the US 
and other developed countries.
    Scientists at NIAID have developed a method of treating or 
preventing atopic dermatitis via the topical application of selected 
probiotic strains of gram-negative Roseomonas mucosa bacteria. This 
approach avoids the exhausting treatment demands of standard therapies 
and has been shown to be beneficial in a preclinical mouse model of 
atopic dermatitis.
    Potential Commercial Applications:

 Treatment of eczema

    Competitive Advantages:

 May be formulated as a cream or ointment

[[Page 69542]]

 Corticosteroid-free
 Animal data available

    Development Stage:

 In vivo data available (animal)

    Inventors: Ian A. Myles, Sandip Kumar Datta, all of NIAID.
    Publications: Myles IA, et al. Transplantation of human skin 
microbiota in models of atopic dermatitis. JCI Insight, 2016, Jul 7; 
1(10). [PMID 27478874].
    Intellectual Property: HHS Reference No. E-099-2016/0--US Patent 
Application No. 62/324,762 filed April 19, Year 2016.
    Licensing Contact: Dr. David Yang, 240-627-3413; 
[email protected]. Collaborative Research Opportunity: The National 
Institute of Allergy and Infectious Diseases is seeking statements of 
capability or interest from parties interested in collaborative 
research to further develop, evaluate or commercialize the use of 
Roseomonas species to treat eczematous (atopic dermatitis) skin 
disease. For collaboration opportunities, please contact Dr. David 
Yang, 240-627-3413; [email protected].

    Dated: Septenber 30, 2016.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2016-24134 Filed 10-5-16; 8:45 am]
BILLING CODE 4140-01-P